Oxford Biomedica Receives Notice of Allowance for U.S. Patent

Oxford BioMedica, the leading gene therapy company, announces that they have received a notice of allowance from the U.S. Patent Office for a patent containing broad claims covering modifications to lentiviral vectors that improve safety and efficacy. Oxford BioMedica owns an extensive portfolio of broad patents and patent applications covering many aspects of the composition of matter and use of gene delivery systems based on lentiviral vectors.

Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=21936&nfid=mnf)